Wei Hu, Wen-Ming Chen, Jun-Bo Jiao
Department of Oncology, Jining No.1 People's Hospital, Jining, Shandong Province, China.
J Int Med Res. 2017 Jun;45(3):1054-1060. doi: 10.1177/0300060517709614. Epub 2017 May 23.
Objectives The objective of this study was to evaluate levels of plasma miR-145 in patients with cervical cancer (CC) and investigate its biomarker potential. Methods Using qRT-PCR, we compared plasma miR-145 levels in 120 patients with CC, 120 patients with cervical intraepithelial neoplasia (CIN), and 120 healthy volunteers. The association between plasma miR-145 expression and clinicopathological factors, including radiation response, was also analyzed. Results Plasma miR-145 levels were lower in CC patient than in CIN patients and healthy controls. Low levels were significantly associated with poor cancer differentiation, lymph node metastasis, HPV, and advanced FIGO stage. CC patients who achieved complete response to radiotherapy had higher plasma miR-145 levels than incomplete responders. ROC analysis confirmed that plasma miR-145 is a candidate biomarker for detecting CC and differentiating complete responders from incomplete responders. Conclusions Plasma miR-145 is reduced in CC and is a novel candidate biomarker for diagnosing CC and predicting radiosensitivity.
目的 本研究的目的是评估宫颈癌（CC）患者血浆miR-145水平，并研究其作为生物标志物的潜力。方法 采用qRT-PCR，我们比较了120例CC患者、120例宫颈上皮内瘤变（CIN）患者和120名健康志愿者的血浆miR-145水平。还分析了血浆miR-145表达与包括放射反应在内的临床病理因素之间的关联。结果 CC患者的血浆miR-145水平低于CIN患者和健康对照。低水平与癌症分化差、淋巴结转移、HPV感染及FIGO晚期显著相关。对放疗达到完全缓解的CC患者血浆miR-145水平高于未完全缓解者。ROC分析证实，血浆miR-145是检测CC以及区分完全缓解者与未完全缓解者的候选生物标志物。结论 CC患者血浆miR-145水平降低，是诊断CC和预测放射敏感性的新型候选生物标志物。
